13 November 2012
Responding to the publication of the Government’s mandate to the NHS Commissioning Board, Duleep Allirajah, Head of Policy at Macmillan Cancer Support, says:
“We are pleased that the Government has recommended a new measurement for survival rates for all cancers, alongside the ‘big three’ (lung, breast and colorectal cancer). This will help to ensure that people with rarer cancers are not discriminated against.
“It is also encouraging that the Government wants the NHS to be recognised globally as having the highest standards of care for people at the end of life so more people can die in their place of choice.
“However, in order for these priorities to become a reality, there needs to be accountability at a local level as well as at the national level. It is vital that Clinical Commissioning Groups are held to account for survival rates for all cancers and their delivery of patient choice in end of life care.”
For further information, please contact:
Claire Keuls, Media & PR Officer
020 7840 4872 (out of hours 07801 307068)
Notes to Editors:
1 Department of Health, (2012) The Mandate: A Mandate from the Government to the NHS Commissioning Board: April 2013 to March 2015
2 The NHS Outcomes Framework has been published as part of the Mandate, which includes an indicator on one and five year survival from all cancers.
About Macmillan Cancer Support
Cancer is the toughest fight most of us will ever face. But you don’t have to go through it alone. The Macmillan team is with you every step of the way.
We are the nurses and therapists helping you through treatment. The experts on the end of the phone. The advisers telling you which benefits you’re entitled to. The volunteers giving you a hand with the everyday things. The campaigners improving cancer care. The fundraisers who make it all possible.
We are Macmillan Cancer Support